ClinicalTrials.gg

Program

YN001

A development code. Also written as “YN001, Rosuvastatin calcium Tablets”, “Dose 1 YN001” and “Dose 2 YN001”.

Its studies are mostly in Atherosclerosis · Coronary Artery Disease · Cerebrovascular Disorders · Cardiovascular Diseases, led by Beijing Inno Medicine.

Furthest: phase 2, since Sep 16, 20236 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Inno Medicine61 open or runningphase 2since Sep 16, 2023Oct 20, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2022First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT05635084 · 64 enrolled · Australia
  2. Sep 16, 2023Phase 2 study in AtherosclerosisNCT06048588 · 144 enrolled · China
  3. Nov 14, 2024Phase 2 study in Coronary Artery DiseaseNCT06700720 · 3 enrolled · Australia
  4. Sep 17, 2025Phase 1 study in Healthy VolunteersNCT07190885 · 24 enrolled · Australia
  5. Nov 19, 2025Phase 2 study in AtherosclerosisNCT07311330 · 40 planned · China
  6. Nov 27, 2025Phase 1 study in Cerebrovascular DisordersNCT07309042 · 24 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07309042Cerebrovascular Disorders · China1CompletedMar 30, 202624
NCT07311330Atherosclerosis · China2RecruitingOct 202640
NCT07190885Healthy Volunteers · Australia1SuspendedSep 202624
NCT06700720Coronary Artery Disease · Australia2TerminatedJul 22, 20263
NCT06048588Atherosclerosis · China2CompletedApr 27, 2025144
NCT05635084Cardiovascular Diseases · Australia1CompletedAug 9, 202464

How it is read

Names in the registry

  • “YN001, Rosuvastatin calcium Tablets”, 3 entries
  • “YN001”, 3 entries
  • “Dose 1 YN001”, 1 entry
  • “Dose 2 YN001”, 1 entry
  • “YN001 20mg Dose + 5% glucose injection”, 1 entry

Codes read as this program: YN001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.